{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:07:04Z","timestamp":1782961624003,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018562","name":"Social Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients\u2019 survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)\/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient\u2019s immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months.<\/jats:p>","DOI":"10.3389\/fonc.2023.1124730","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:00:55Z","timestamp":1678770055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR\/MSS colorectal cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2019.01243","article-title":"Rapid advances in research on and development of anticancer drugs in China","volume":"13","author":"Yao","year":"2019","journal-title":"Biosci Trends"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: A systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1933940","article-title":"Targeting MSS colorectal cancer with immunotherapy: Are we turning the corner","volume":"21","author":"Wang","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0875","article-title":"Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase III trial","volume":"17","author":"Xu","year":"2021","journal-title":"Future Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.851756","article-title":"Fruquintinib in combination with PD-1 inhibitors in patients with refractory non-MSI-H\/pMMR metastatic colorectal cancer: A real-world study in China","volume":"12","author":"Gou","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","article-title":"Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases","volume":"181","author":"Guo","year":"2022","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.917353","article-title":"Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy: A real-world study","volume":"12","author":"Nie","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.062","article-title":"Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review","volume":"81","author":"Wang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.032","article-title":"Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid","volume":"159","author":"Shi","year":"2021","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e24804","DOI":"10.7759\/cureus.24804","article-title":"A case of bullous pemphigoid associated with nivolumab therapy","volume":"14","author":"Gotera","year":"2022","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.005","article-title":"Intravenous IgG reduces pathogenic autoantibodies, serum IL-6 levels, and disease severity in experimental bullous pemphigoid models","volume":"138","author":"Sasaoka","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: Current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.023","article-title":"Reply to: \"Comment on 'Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'\"","volume":"87","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01477-w","article-title":"Safety profile and adverse events of special interest for fruquintinib in Chinese patients with previously treated metastatic colorectal cancer: Analysis of the phase 3 FRESCO trial","volume":"37","author":"Li","year":"2020","journal-title":"Adv Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1124730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T05:00:58Z","timestamp":1678770058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1124730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":23,"alternative-id":["10.3389\/fonc.2023.1124730"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1124730","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"article-number":"1124730"}}